These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 36478896)
1. Role of SHP2/PTPN11 in the occurrence and prognosis of cancer: A systematic review and meta-analysis. Li S; Wang X; Li Q; Li C Oncol Lett; 2023 Jan; 25(1):19. PubMed ID: 36478896 [TBL] [Abstract][Full Text] [Related]
2. SHP2 is involved in the occurrence, development and prognosis of cancer. Li S; Qu J; Wang X; Zou Q; Li C Oncol Lett; 2023 Sep; 26(3):393. PubMed ID: 37600341 [TBL] [Abstract][Full Text] [Related]
3. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of SHP2 (PTPN11) expression in solid tumors: A meta-analysis. Zhou J; Guo H; Zhang Y; Liu H; Dou Q PLoS One; 2022; 17(1):e0262931. PubMed ID: 35061863 [TBL] [Abstract][Full Text] [Related]
5. The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma. Jiang C; Hu F; Tai Y; Du J; Mao B; Yuan Z; Wang Y; Wei L J Cancer Res Clin Oncol; 2012 Apr; 138(4):637-46. PubMed ID: 22228034 [TBL] [Abstract][Full Text] [Related]
7. Association of nuclear localization of SHP2 and YAP1 with unfavorable prognosis in non-small cell lung cancer. Chen MJ; Wang YC; Wu DW; Chen CY; Lee H Pathol Res Pract; 2019 Apr; 215(4):801-806. PubMed ID: 30685130 [TBL] [Abstract][Full Text] [Related]
8. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies. Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065 [TBL] [Abstract][Full Text] [Related]
9. Polyphyllin D Shows Anticancer Effect through a Selective Inhibition of Src Homology Region 2-Containing Protein Tyrosine Phosphatase-2 (SHP2). Kwon SJ; Ahn D; Yang HM; Kang HJ; Chung SJ Molecules; 2021 Feb; 26(4):. PubMed ID: 33562835 [TBL] [Abstract][Full Text] [Related]
10. Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies. Liu X; Zheng H; Li X; Wang S; Meyerson HJ; Yang W; Neel BG; Qu CK Proc Natl Acad Sci U S A; 2016 Jan; 113(4):984-9. PubMed ID: 26755576 [TBL] [Abstract][Full Text] [Related]
11. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis. Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348 [TBL] [Abstract][Full Text] [Related]
12. Modeling (not so) rare developmental disorders associated with mutations in the protein-tyrosine phosphatase SHP2. Solman M; Woutersen DTJ; den Hertog J Front Cell Dev Biol; 2022; 10():1046415. PubMed ID: 36407105 [TBL] [Abstract][Full Text] [Related]
13. Expression and clinical significance of SHP2 in gastric cancer. Dong S; Li FQ; Zhang Q; Lv KZ; Yang HL; Gao Y; Yu JR J Int Med Res; 2012; 40(6):2083-9. PubMed ID: 23321164 [TBL] [Abstract][Full Text] [Related]
14. T cell-specific constitutive active SHP2 enhances T cell memory formation and reduces T cell activation. Cammann C; Israel N; Frentzel S; Jeron A; Topfstedt E; Schüler T; Simeoni L; Zenker M; Fehling HJ; Schraven B; Bruder D; Seifert U Front Immunol; 2022; 13():958616. PubMed ID: 35983034 [TBL] [Abstract][Full Text] [Related]
15. [The Biological Function of SHP2 in Human Disease]. Li SM Mol Biol (Mosk); 2016; 50(1):27-33. PubMed ID: 27028808 [TBL] [Abstract][Full Text] [Related]
16. Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders. Tang K; Jia YN; Yu B; Liu HM Eur J Med Chem; 2020 Oct; 204():112657. PubMed ID: 32738411 [TBL] [Abstract][Full Text] [Related]
17. Induction of a tumor-associated activating mutation in protein tyrosine phosphatase Ptpn11 (Shp2) enhances mitochondrial metabolism, leading to oxidative stress and senescence. Zheng H; Li S; Hsu P; Qu CK J Biol Chem; 2013 Sep; 288(36):25727-25738. PubMed ID: 23884424 [TBL] [Abstract][Full Text] [Related]
18. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Chan G; Kalaitzidis D; Neel BG Cancer Metastasis Rev; 2008 Jun; 27(2):179-92. PubMed ID: 18286234 [TBL] [Abstract][Full Text] [Related]
19. A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors. Romero C; Lambert LJ; Sheffler DJ; De Backer LJS; Raveendra-Panickar D; Celeridad M; Grotegut S; Rodiles S; Holleran J; Sergienko E; Pasquale EB; Cosford NDP; Tautz L J Biol Chem; 2020 Feb; 295(9):2601-2613. PubMed ID: 31953320 [TBL] [Abstract][Full Text] [Related]
20. Counteracting effects operating on Src homology 2 domain-containing protein-tyrosine phosphatase 2 (SHP2) function drive selection of the recurrent Y62D and Y63C substitutions in Noonan syndrome. Martinelli S; Nardozza AP; Delle Vigne S; Sabetta G; Torreri P; Bocchinfuso G; Flex E; Venanzi S; Palleschi A; Gelb BD; Cesareni G; Stella L; Castagnoli L; Tartaglia M J Biol Chem; 2012 Aug; 287(32):27066-77. PubMed ID: 22711529 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]